The phase II study of pembrolizumab plus lenvatinib for patients with unresectable cutaneous angiosarcoma (Pembro-Lenva for cAS/PLAS trial). A multicenter, randomized, global phase 3 study to assess ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results